Discovery of triterpenoids as reversible inhibitors of α/β- hydrolase domain containing 12 (ABHD12)

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Parkkari, Teija ^a   Haavikko, Raisa ^b   Laitinen, Tuomo ^a   Navia Paldanius, Dina ^a   Rytilahti, Roosa ^a   Vaara, Miia ^a   Lehtonen, Marko ^a   Alakurtti, Sami ^b,c   Yli Kauhaluoma, Jari ^b   Nevalainen, Tapio ^a   Savinainen, Juha R ^a   Laitinen, Jarmo T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1H 1,2,4 TRIAZOL 1 YL)BETULONONE; 2BETA, 3BETA DIHYDROXYLUP 20(29) EN 28 OIC ACID; ALPHA BETA HYDROLASE DOMAIN CONTAINING 12 PROTEIN; CANNABINOID RECEPTOR; CARBOXYL GROUP; HYDROLASE; LUPA 2,20(29) DIENO[2,3 B]PYRIDIN 28 OIC ACID; PROTEOME; TRITERPENE; TRITERPENOID; UNCLASSIFIED DRUG; ABHD12 PROTEIN, HUMAN; ACYLGLYCEROL LIPASE; ENZYME INHIBITOR; LIGAND;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; ENZYME SPECIFICITY; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR DOCKING; MOUSE; PROTEIN CONFORMATION;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; LIGANDS; MICE; MOLECULAR DOCKING SIMULATION; MONOACYLGLYCEROL LIPASES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRITERPENES;

EID: 84902336189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098286     Document Type: Article

References (35)

1. Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356. (Pubitemid 350257008)
2. Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013) ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci U S A 110: 1500-1505.
3. Fiskerstrand T, H'Mida-Ben Brahim D, Johansson S, M'Zahem A, Haukanes BI, et al. (2010) Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism. Am J Hum Genet 87: 410-417.
4. Navia-Paldanius D, Savinainen JR, Laitinen JT (2012) Biochemical and pharmacological characterization of human alpha/beta-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J Lipid Res 53: 2413-2424.
5. Jager S, Trojan H, Kopp T, Laszczyk MN, Scheffler A (2009) Pentacyclic triterpene distribution in various plants - rich sources for a new group of multipotent plant extracts. Molecules 14: 2016-2031.
6. Moura-Letts G, Villegas LF, Marcalo A, Vaisberg AJ, Hammond GB (2006) In vivo wound-healing activity of oleanolic acid derived from the acid hydrolysis of Anredera diffusa. J Nat Prod 69: 978-979. (Pubitemid 44166279)
7. He X, Liu RH (2007) Triterpenoids isolated from apple peels have potent antiproliferative activity and may be partially responsible for apple's anticancer activity. J Agric Food Chem 55: 4366-4370.
8. Li L, Zhang X, Cui L, Wang L, Liu H, et al. (2013) Ursolic acid promotes the neuroprotection by activating Nrf2 pathway after cerebral ischemia in mice. Brain Res 1497: 32-39.
9. Siewert B, Wiemann J, Köwitsch A, Csuk R (2013) The chemical and biological potential of C ring modified triterpenoids. Eur J Med Chem 72: 84-101.
10. Alakurtti S, Makela T, Koskimies S, Yli-Kauhaluoma J (2006) Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1-13. (Pubitemid 44279394)
11. Castellano JM, Guinda A, Delgado T, Rada M, Cayuela JA (2013) Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. Diabetes 62: 1791-1799.
12. Fulda S (2008) Betulinic acid for cancer treatment and prevention. Int J Mol Sci 9: 1096-107.
13. Pollier J, Goossens A (2012) Oleanolic acid. Phytochemistry 77: 10-15.
14. Yadav VR, Prasad S, Sung B, Kannappan R, Aggarwal BB (2010) Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel) 2: 2428-2466.
15. Safe SH, Prather PL, Brents LK, Chadalapaka G, Jutooru I (2012) Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem 12: 1211-1220.
16. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J (2008) Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci 65: 2979-2999.
17. King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, et al. (2009) Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol 16: 1045-1052.
18. Laitinen T, Navia-Paldanius D, Rytilahti R, Marjamaa J, Kařízková J, et al. (2014) Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency. Mol Pharmacol 85: 510-519.
19. da Silva K, Paszcuk A, Passos G, Silva E, Bento A, et al. (2011) Activation of cannabinoid receptors by the pentacyclic triterpene α,β-amyrin inhibits inflammatory and neuropathic persistent pain in mice. Pain 152: 1872-1887.
20. Chicca A, Marazzi J, Gertsch J (2012) The antinociceptive triterpene beta-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br J Pharmacol 167: 1596-1608.
21. Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, et al. (2010) Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 53: 178-190.
22. Liu Q, Liu H, Zhang L, Guo T, Wang P, et al. (2013) Synthesis and antitumor activities of naturally occurring oleanolic acid triterpenoid saponins and their derivatives. Eur J Med Chem 64: 1-15.
23. Gao H, Wu L, Kuroyanagi M, Harada K, Kawahara N, et al. (2003) Antitumor-promoting constituents from Chaenomeles sinensis KOEHNE and their activities in JB6 mouse epidermal cells. Chem Pharm Bull (Tokyo) 51: 1318-1321. (Pubitemid 41685594)
24. Alakurtti S, Heiska T, Kiriazis A, Sacerdoti-Sierra N, Jaffe CL, et al. (2010) Synthesis and anti-leishmanial activity of heterocyclic betulin derivatives. Bioorg Med Chem 18: 1573-1582.
25. Pohjala L, Alakurtti S, Ahola T, Yli-Kauhaluoma J, Tammela P (2009) Betulin-derived compounds as inhibitors of alphavirus replication. J Nat Prod 72: 1917-1926.
26. Kumar NS, Muthukuda PM, Wazeer MIM (1985) A lupenediol from Euonymus revolutus. Phytochemistry 24: 1337-1340.
27. Haavikko R, Nasereddin A, Sacerdoti-Sierra N, Kopelyanskiy D, Alakurtti S, et al. (2014) Heterocycle-fused lupane triterpenoids inhibit Leishmania donovani amastigotes. Med Chem Commun 5: 445-451.
28. Hao J, Sun H, Zhang P, Zhang X, Liu J, et al. (2009) Efficient access to isomeric 2,3-dihydroxy lupanes: first synthesis of alphitolic acid. Tetrahedron 65: 7975-7984.
29. Santos RC, Salvador JA, Marin S, Cascante M, Moreira JN, et al. (2010) Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid. Bioorg Med Chem 18: 4385-4396.
30. Saario SM, Poso A, Juvonen RO, Jarvinen T, Salo-Ahen OM (2006) Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem 49: 4650-4656. (Pubitemid 44162691)
31. Aaltonen N, Savinainen JR, Ribas CR, Ronkko J, Kuusisto A, et al. (2013) Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem Biol 20: 379-390.
32. Savinainen JR, Kokkola T, Salo OM, Poso A, Jarvinen T, et al. (2005) Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 145: 636-645. (Pubitemid 41032635)
33. Savinainen JR, Saario SM, Niemi R, Jarvinen T, Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140: 1451-1459. (Pubitemid 38067852)
34. Hoover HS, Blankman JL, Niessen S, Cravatt BF (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett 18: 5838-5841.
35. Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, et al. (2013) Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem 56: 8484-8496.